• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Psychosocial issues in erythropoietic protoporphyria - the perspective of parents, children, and young adults: A qualitative study.红细胞生成性原卟啉症的心理社会问题 - 父母、儿童和青年的观点:一项定性研究。
Mol Genet Metab. 2019 Nov;128(3):314-319. doi: 10.1016/j.ymgme.2019.01.023. Epub 2019 Jan 26.
2
Quality of life in children with erythropoietic protoporphyria: a case-control study.红细胞生成性原卟啉病患儿的生活质量:一项病例对照研究。
J Dermatol. 2024 Aug;51(8):1068-1078. doi: 10.1111/1346-8138.17348. Epub 2024 Jun 26.
3
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.北美红细胞生成性原卟啉症和X连锁原卟啉症患者的临床、生化及遗传学特征
JAMA Dermatol. 2017 Aug 1;153(8):789-796. doi: 10.1001/jamadermatol.2017.1557.
4
Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria.红细胞生成性原卟啉症患者阳光暴露日记的制定和内容验证。
J Patient Rep Outcomes. 2023 Nov 20;7(1):119. doi: 10.1186/s41687-023-00655-y.
5
Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria.基于证据的共识指南,用于诊断和管理红细胞生成性原卟啉症和 X 连锁原卟啉症。
J Am Acad Dermatol. 2023 Dec;89(6):1227-1237. doi: 10.1016/j.jaad.2022.08.036. Epub 2022 Aug 27.
6
Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.红细胞生成性原卟啉症和 X 连锁原卟啉症:病理生理学、遗传学、临床表现和治疗。
Mol Genet Metab. 2019 Nov;128(3):298-303. doi: 10.1016/j.ymgme.2019.01.020. Epub 2019 Jan 24.
7
Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life.英国的红细胞生成性原卟啉病:临床特征及对生活质量的影响。
Br J Dermatol. 2006 Sep;155(3):574-81. doi: 10.1111/j.1365-2133.2006.07472.x.
8
Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X-linked protoporphyria.评估北美红细胞生成性原卟啉病和X连锁原卟啉病患者的生活质量工具
JIMD Rep. 2019 Sep 14;50(1):9-19. doi: 10.1002/jmd2.12052. eCollection 2019 Nov.
9
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.阿法美拉肽预防红细胞生成性原卟啉症中的光毒性作用
Expert Rev Clin Pharmacol. 2021 Feb;14(2):151-160. doi: 10.1080/17512433.2021.1879638.
10
Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide.荷兰的红细胞生成性原卟啉症:临床特征、社会心理影响及阿法美拉肽的作用
J Dermatol. 2023 Apr;50(4):445-452. doi: 10.1111/1346-8138.16690. Epub 2022 Dec 28.

引用本文的文献

1
The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria.甘氨酸转运体1(GLYT1)抑制剂比特丙醇可减轻红细胞生成性原卟啉症中的红细胞原卟啉(PPIX)生成及肝脏疾病。
J Clin Invest. 2025 Jul 15;135(18). doi: 10.1172/JCI181875. eCollection 2025 Sep 16.
2
Self-Reported Liver Disease and the Burden of Erythropoietic Protoporphyria.自我报告的肝病与红细胞生成性原卟啉症负担
JIMD Rep. 2025 Apr 20;66(3):e70015. doi: 10.1002/jmd2.70015. eCollection 2025 May.
3
A scoping review of health literacy in rare disorders: key issues and research directions.罕见病健康素养的范围综述:关键问题和研究方向。
Orphanet J Rare Dis. 2024 Sep 6;19(1):328. doi: 10.1186/s13023-024-03332-5.
4
Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.阿法美拉肽治疗原卟啉病:对美国一组患者生活质量和实验室参数的影响
Life (Basel). 2024 May 28;14(6):689. doi: 10.3390/life14060689.
5
Quality of life in children with erythropoietic protoporphyria: a case-control study.红细胞生成性原卟啉病患儿的生活质量:一项病例对照研究。
J Dermatol. 2024 Aug;51(8):1068-1078. doi: 10.1111/1346-8138.17348. Epub 2024 Jun 26.
6
Development and Content Validation of Novel Patient-Reported Outcome Measures to Assess Disease Severity and Change in Patients with Erythropoietic Protoporphyria: The EPP Impact Questionnaire (EPIQ).用于评估红细胞生成性原卟啉症患者疾病严重程度和变化的新型患者报告结局指标的开发与内容验证:EPP影响问卷(EPIQ)。
Patient Relat Outcome Meas. 2024 Feb 14;15:17-30. doi: 10.2147/PROM.S438892. eCollection 2024.
7
Roles of the ABCG2 Transporter in Protoporphyrin IX Distribution and Toxicity.ABCG2 转运蛋白在原卟啉 IX 分布和毒性中的作用。
Drug Metab Dispos. 2024 Oct 16;52(11):1201-1207. doi: 10.1124/dmd.123.001582.
8
Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria.红细胞生成性原卟啉症患者阳光暴露日记的制定和内容验证。
J Patient Rep Outcomes. 2023 Nov 20;7(1):119. doi: 10.1186/s41687-023-00655-y.
9
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics.原卟啉 IX 诱导的光毒性:机制与治疗。
Pharmacol Ther. 2023 Aug;248:108487. doi: 10.1016/j.pharmthera.2023.108487. Epub 2023 Jun 29.
10
Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study.红细胞生成性原卟啉症和其他罕见病的质量调整生命年:一项患者发起的 EQ-5D 可行性研究。
Int J Environ Res Public Health. 2023 Mar 28;20(7):5296. doi: 10.3390/ijerph20075296.

本文引用的文献

1
Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations.患者视角下的急性间歇性卟啉症频繁发作:一种间歇性和慢性表现的疾病。
Patient. 2018 Oct;11(5):527-537. doi: 10.1007/s40271-018-0319-3.
2
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.北美红细胞生成性原卟啉症和X连锁原卟啉症患者的临床、生化及遗传学特征
JAMA Dermatol. 2017 Aug 1;153(8):789-796. doi: 10.1001/jamadermatol.2017.1557.
3
Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.急性肝卟啉症复发患者的经历与担忧:一项定性研究。
Mol Genet Metab. 2016 Nov;119(3):278-283. doi: 10.1016/j.ymgme.2016.08.006. Epub 2016 Aug 24.
4
A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda.是皮肤病、血液病还是介于两者之间的病症?一项关于迟发性皮肤卟啉症患者经历的探索性焦点小组研究。
Br J Dermatol. 2015 Jan;172(1):223-9. doi: 10.1111/bjd.13198. Epub 2014 Nov 27.
5
Porphyrin and heme metabolism and the porphyrias.卟啉和血红素代谢与卟啉病。
Compr Physiol. 2013 Jan;3(1):365-401. doi: 10.1002/cphy.c120006.
6
Delayed diagnosis and diminished quality of life in erythropoietic protoporphyria: results of a cross-sectional study in Sweden.红细胞生成性原卟啉症的延迟诊断与生活质量下降:瑞典一项横断面研究的结果
J Intern Med. 2011 Mar;269(3):270-4. doi: 10.1111/j.1365-2796.2010.02283.x. Epub 2010 Nov 14.
7
Erythropoietic protoporphyria.红细胞生成性原卟啉症。
Orphanet J Rare Dis. 2009 Sep 10;4:19. doi: 10.1186/1750-1172-4-19.
8
Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life.英国的红细胞生成性原卟啉病:临床特征及对生活质量的影响。
Br J Dermatol. 2006 Sep;155(3):574-81. doi: 10.1111/j.1365-2133.2006.07472.x.
9
Women's experience of suffering repeated severe attacks of acute intermittent porphyria.
J Adv Nurs. 2000 Dec;32(6):1348-55. doi: 10.1046/j.1365-2648.2000.01628.x.
10
Porphyrias: photosensitivity and phototherapy.
Methods Enzymol. 2000;319:485-93. doi: 10.1016/s0076-6879(00)19045-7.

红细胞生成性原卟啉症的心理社会问题 - 父母、儿童和青年的观点:一项定性研究。

Psychosocial issues in erythropoietic protoporphyria - the perspective of parents, children, and young adults: A qualitative study.

机构信息

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.

出版信息

Mol Genet Metab. 2019 Nov;128(3):314-319. doi: 10.1016/j.ymgme.2019.01.023. Epub 2019 Jan 26.

DOI:10.1016/j.ymgme.2019.01.023
PMID:30711301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6660424/
Abstract

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare photodermatoses, generally presenting in childhood with severe and painful phototoxicity. EPP has been reported to negatively affect quality of life (QoL), but there is limited information on the psychosocial issues faced by patients and families. To address this, an online focus group study was conducted to explore the perspective of parents of children with EPP, and young adults and children with EPP. Five focus groups were conducted in a semi-structured format, with moderator-led discussions exploring the impact on QoL. Three focus groups included parents of children with EPP, one with children aged 10-11 years, and another with young adults aged 24-25 years, for a total of 24 participants. Thematic data analysis showed that parents experience guilt for being unable to protect their children and frustration with the current state of knowledge of EPP. Parents also admitted that the disease can lead to stress within family members which is difficult to manage. Young adults expressed embarrassment over having to explain the disease to others. They reported that the teenage years were the most difficult to navigate; however, they learned to adapt to their disease as they grew older. Children expressed that they had limited understanding of their disease and wished they were told what symptoms to expect by physicians earlier in life. Our findings emphasize the significant impact on QoL for these families and a lack of age appropriate information for children with EPP. These findings can help improve counseling and support resources for patients and caregivers.

摘要

红细胞生成性原卟啉症(EPP)和 X 连锁原卟啉症(XLP)是罕见的光皮病,通常在儿童时期出现严重且疼痛的光毒性。据报道,EPP 会对生活质量(QoL)产生负面影响,但有关患者和家属所面临的心理社会问题的信息有限。为了解决这一问题,我们进行了一项在线焦点小组研究,以探讨 EPP 患儿家长以及年轻患者的观点。我们以半结构化的方式进行了五次焦点小组讨论,由主持人引导讨论,以探讨 QoL 的影响。其中三个焦点小组包括 EPP 患儿的家长,一个小组的参与者是 10-11 岁的儿童,另一个小组的参与者是 24-25 岁的年轻人,共有 24 名参与者。主题数据分析表明,父母因无法保护孩子而感到内疚,并对 EPP 的现有知识状况感到沮丧。家长们还承认,这种疾病会导致家庭成员之间的压力,而这种压力很难管理。年轻人表示,他们不得不向他人解释这种疾病感到尴尬。他们报告说,青少年时期是最困难的时期;然而,随着年龄的增长,他们学会了适应自己的疾病。儿童表示,他们对自己的疾病了解有限,希望医生能更早地告诉他们会出现哪些症状。我们的研究结果强调了这些家庭的 QoL 受到重大影响,并且缺乏针对 EPP 患儿的适当年龄的信息。这些发现可以帮助改善患者和照顾者的咨询和支持资源。